Table 1.
Baseline patient characteristics at TAVR*
| All (n = 23) | RF < 20% (n = 11) | RF > 20% (n = 12) | P value | |
|---|---|---|---|---|
| Male | 16 (70) | 6 (55) | 10 (83) | 0.19 |
| Age (mean ± SD) | 83 ± 6 | 83 ± 7 | 82 ± 5 | 0.86 |
| NYHA class (mean ± SD) | 3.2 ± 0.7 | 3.1 ± 0.7 | 3.3 ± 0.8 | 0.61 |
| STS-PROM (%; mean ± SD) | 6.9 ± 2.4 | 6.4 ± 2.0 | 7.4 ± 2.7 | 0.33 |
| Body mass index (kg/m2) | 25 ± 4 | 25 ± 4 | 24 ± 4 | 0.64 |
| Comorbidities | ||||
| Coronary artery disease | 13 (57) | 7 (64) | 6 (50) | 0.68 |
| CABG | 7 (30) | 2 (18) | 5 (42) | |
| PCI | 8 (35) | 4 (36) | 4 (33) | |
| Myocardial infarction | 7 (30) | 3 (27) | 4 (33) | |
| Atrial fibrillation | 10 (44) | 2 (18) | 8 (67) | 0.04 |
| Diabetes mellitus | 10 (44) | 5 (46) | 5 (42) | 1.00 |
| Hypertension | 21 (91) | 10 (91) | 11 (92) | 1.00 |
| Serum creatinine >1.5 mg/dl |
8 (35) | 2 (18) | 6 (50) | 0.19 |
| COPD | 8 (35) | 3 (27) | 5 (42) | 0.67 |
| Laboratory | ||||
| Creatinine (mg/dl; median [IQR]) | 1.11 (0.90, 1.61) | 1.07 (1.00, 1.30) | 1.45 (0.86, 1.89) | 0.18 |
| BNP (pg/ml; median [IQR]) | 545 (226, 1612) | 297 (197, 843) | 1385 (360, 1806) | 0.17 |
| Echocardiography | ||||
| Ejection fraction (%; mean ± SD) | 47 ± 14 | 45 ± 13 | 49 ± 15 | 0.46 |
| Aortic insufficiency* (mean ± SD) | 1.1 ± 0.7 | 1.0 ± 0.7 | 1.1 ± 0.7 | 0.90 |
| RVSP (mmHg; mean ± SD) | 48 ± 17 | 43 ± 12 | 53 ± 19 | 0.17 |
| RVSP >55 mmHg | 7 (30) | 2 (18) | 5 (42) | 0.37 |
| Transfemoral approach | 17 (74) | 6 (55) | 11 (92) | 0.07 |
*All results are presented as n (%) unless otherwise noted.
BNP = brain natriuretic peptide, CABG = coronary artery bypass grafting, COPD = chronic obstructive pulmonary disease, IQR = interquartile range, NYHA = New York Heart Association, PCI = percutaneous coronary intervention, RVSP = right ventricular systolic pressure, STS-PROM = Society of Thoracic Surgeons predicted risk of mortality, TAVR = transcatheter aortic valve replacement.